Exicure Inc (XCUR)

$6.74 +1.18 (21.22%)
Market Cap 35.44M
Revenue (ttm) 500,000.00
Net Income (ttm) -9.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,940.00%
Debt to Equity Ratio 0.00
Volume 70,400
Avg Vol 32,926
Day's Range N/A - N/A
Shares Out 6.37M
Stochastic %K 98%
Beta 4.08
Analysts Strong Buy
Price Target $2.00

Company Profile

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 847 673 1700
Address:
400 Seaport Court, Suite 102, Redwood City, United States
SadyK189
SadyK189 Dec. 5 at 2:56 AM
Top Stocks to watch tomorrow 2 / 2: $AKAN $XCUR $SUGP $VRAX $IXHL VRAX: Looking good on 4hours chart. Key support 0.53 - 0.57. Next key level to test is 0.78 - 0.83. Currently at 0.65. IXHL has held key support zone of 0.37 - 0.41 nicely so far. Next key level to test is 0.56 - 0.59. Currently at 0.47. AKAN: Good close of 4hours candle. 0.9 - 1.05 is acting as key support zone. Next key level to test is 1.7 - 1.82. Currently at 1.38 XCUR is moving slowly and steadily but nicely on daily chart. Key support at 5.4 - 5.8. Next key level to test is 7.6 - 8.1. Currently at 6.69 SUGP has made a move After hours. Currently at 8.40. It can test 9.75 - 10.30 zone again.
0 · Reply
cfvk
cfvk Dec. 5 at 12:32 AM
$XCUR Scooby do
0 · Reply
Wildblitz
Wildblitz Dec. 4 at 10:29 PM
$XCUR Hopefully u guys get 36 like I did last year- GLTA
0 · Reply
ProfitsBee
ProfitsBee Dec. 4 at 9:56 PM
$SNSE Keep an eye on that $11,44 momentum trigger for a big move north. Float is extremely small here. Could go parabolic with volume Kind of reminds me of $XCUR $VRAX $SMX
0 · Reply
ppl_first
ppl_first Dec. 4 at 8:31 PM
$XCUR major ingress today for what?
0 · Reply
WickedShadows
WickedShadows Dec. 4 at 6:18 PM
Massive news on ticker DEVS🚀 Squeezing right now!! "DevvStream And Southern Energy Secure Louisiana Community Development Authority Approval For $402M Biomass-To-Fuel Facility Project ." With 2M float this can go massive! It's going bulls, don't be late. $GNPX $ZEO $XCUR $OPEN 12
0 · Reply
MoonWatchers
MoonWatchers Dec. 4 at 1:43 PM
$XCUR news?
1 · Reply
Pinecone_Tradingz_
Pinecone_Tradingz_ Dec. 3 at 1:28 PM
$XCUR Ready for a move to 7+
0 · Reply
durrma
durrma Dec. 2 at 10:00 PM
$ADAPY $XCUR
0 · Reply
StockScanners
StockScanners Dec. 2 at 3:15 AM
$XCUR keep watch if this holds above 4.88
0 · Reply
Latest News on XCUR
Exicure, Inc. Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 4:00 PM EST - 27 days ago

Exicure, Inc. Reports Third Quarter 2025 Financial Results

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 4:15 PM EDT - 6 weeks ago

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Oct 6, 2025, 7:00 AM EDT - 2 months ago

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Exicure Posts Wider Loss in Fiscal Q2

Aug 8, 2025, 4:19 PM EDT - 4 months ago

Exicure Posts Wider Loss in Fiscal Q2

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 4:01 PM EDT - 4 months ago

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Aug 4, 2025, 4:37 PM EDT - 4 months ago

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Aug 1, 2025, 4:01 PM EDT - 4 months ago

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Reports First Quarter 2025 Financial Results

Jun 27, 2025, 4:01 PM EDT - 5 months ago

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025, 4:58 PM EDT - 6 months ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

May 5, 2025, 8:00 AM EDT - 7 months ago

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Apr 14, 2025, 6:11 PM EDT - 8 months ago

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Apr 11, 2025, 7:42 PM EDT - 8 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Reports Full Year 2024 Financial Results

Mar 18, 2025, 4:01 PM EDT - 9 months ago

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Mar 13, 2025, 4:08 PM EDT - 9 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 23, 2025, 12:17 AM EST - 11 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 22, 2025, 4:01 PM EST - 11 months ago

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Dec 26, 2024, 8:08 PM EST - 1 year ago

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 21, 2024, 1:48 PM EST - 1 year ago

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 20, 2024, 4:42 PM EST - 1 year ago

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Sep 18, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Aug 26, 2024, 9:08 AM EDT - 1 year ago

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 19, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 15, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Aug 8, 2024, 4:27 PM EDT - 1 year ago

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure, Inc. Reports First Quarter 2024 Financial Results

Jun 17, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. Reports Full Year 2023 Financial Results

Jun 6, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 23, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. Reports Third Quarter 2023 Financial Results

May 16, 2024, 4:08 PM EDT - 1 year ago

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Apr 22, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Feb 5, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Aug 23, 2023, 9:48 AM EDT - 2 years ago

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Jul 14, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 26, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

May 4, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 27, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Feb 24, 2023, 5:10 PM EST - 3 years ago

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Dec 14, 2022, 5:00 AM EST - 3 years ago

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:01 PM EST - 3 years ago

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Sep 26, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Aug 15, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 20, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Jun 29, 2022, 12:00 PM EDT - 3 years ago

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

May 27, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

May 17, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

SadyK189
SadyK189 Dec. 5 at 2:56 AM
Top Stocks to watch tomorrow 2 / 2: $AKAN $XCUR $SUGP $VRAX $IXHL VRAX: Looking good on 4hours chart. Key support 0.53 - 0.57. Next key level to test is 0.78 - 0.83. Currently at 0.65. IXHL has held key support zone of 0.37 - 0.41 nicely so far. Next key level to test is 0.56 - 0.59. Currently at 0.47. AKAN: Good close of 4hours candle. 0.9 - 1.05 is acting as key support zone. Next key level to test is 1.7 - 1.82. Currently at 1.38 XCUR is moving slowly and steadily but nicely on daily chart. Key support at 5.4 - 5.8. Next key level to test is 7.6 - 8.1. Currently at 6.69 SUGP has made a move After hours. Currently at 8.40. It can test 9.75 - 10.30 zone again.
0 · Reply
cfvk
cfvk Dec. 5 at 12:32 AM
$XCUR Scooby do
0 · Reply
Wildblitz
Wildblitz Dec. 4 at 10:29 PM
$XCUR Hopefully u guys get 36 like I did last year- GLTA
0 · Reply
ProfitsBee
ProfitsBee Dec. 4 at 9:56 PM
$SNSE Keep an eye on that $11,44 momentum trigger for a big move north. Float is extremely small here. Could go parabolic with volume Kind of reminds me of $XCUR $VRAX $SMX
0 · Reply
ppl_first
ppl_first Dec. 4 at 8:31 PM
$XCUR major ingress today for what?
0 · Reply
WickedShadows
WickedShadows Dec. 4 at 6:18 PM
Massive news on ticker DEVS🚀 Squeezing right now!! "DevvStream And Southern Energy Secure Louisiana Community Development Authority Approval For $402M Biomass-To-Fuel Facility Project ." With 2M float this can go massive! It's going bulls, don't be late. $GNPX $ZEO $XCUR $OPEN 12
0 · Reply
MoonWatchers
MoonWatchers Dec. 4 at 1:43 PM
$XCUR news?
1 · Reply
Pinecone_Tradingz_
Pinecone_Tradingz_ Dec. 3 at 1:28 PM
$XCUR Ready for a move to 7+
0 · Reply
durrma
durrma Dec. 2 at 10:00 PM
$ADAPY $XCUR
0 · Reply
StockScanners
StockScanners Dec. 2 at 3:15 AM
$XCUR keep watch if this holds above 4.88
0 · Reply
Xavier_Choi
Xavier_Choi Dec. 1 at 9:00 PM
$XCUR LFG!!!🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
topstockalerts
topstockalerts Dec. 1 at 6:59 PM
$XCUR setting up nicely.. 💪
0 · Reply
MadMaverick
MadMaverick Dec. 1 at 6:14 PM
$NDRA is redefining the future of Point-of-Care Diagnostics! 🔹Focused on proprietary Thermo Acoustic Enhanced UltraSound (TAEUS®) for non-invasive liver health. 🔹Backed by $14.4M recent strategic financing & innovative Digital Asset Treasury (HYPE staking). 🔹Positioned as a disruptor in the $30B+ MASLD/MASH monitoring market. Watching for a breakout over $6.10 (MACD bullish divergence & pending EMA crossover) Communicated Disclaimer – https://chartingdaily.com/liver-health-breakthrough Other Biotech's moving up: $KALA $XCUR $CAPR
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 1 at 5:25 PM
$XCUR thin
0 · Reply
Majid74
Majid74 Dec. 1 at 5:05 PM
$XCUR it moves slowly and healthy
0 · Reply
Majid74
Majid74 Dec. 1 at 5:04 PM
$XCUR any news???
0 · Reply
Irakli2508
Irakli2508 Nov. 28 at 2:03 PM
$XCUR
0 · Reply
cfvk
cfvk Nov. 19 at 6:38 PM
$XCUR now actually get volume and rip to 7 - 9
0 · Reply
A1DAYTRADER
A1DAYTRADER Nov. 19 at 6:36 PM
$SGBX $WSHP $XCUR $FRGT $CHR.X $WSHP OVER 1,000% FROM MY ALERT!!🤫🚀💵🚨🚨 GET MY ALERTS EARLY!🙏
0 · Reply
cfvk
cfvk Nov. 18 at 6:09 PM
$XCUR almost 10k bid at 3.7, i'll add a starter here at 3.73, tight stop.
1 · Reply
Bradnum1
Bradnum1 Nov. 14 at 1:49 PM
$XCUR I like this at these prices
0 · Reply
aletz
aletz Nov. 13 at 3:36 PM
$XCUR https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ Exactly same rank as last week. Cash runway seems bit concerning.
0 · Reply